Professor Thomas Borody

Dr Borody is known world-wide for two key contributions: Development and advancement of Faecal Microbiota Transplantation (FMT) techniques for infectious diseases of the gut microbiome (such as C. difficile, ulcerative colitis, Irritable Bowel Syndrome (IBS), Crohn’s disease including the invention of lyophilised faecal microbiota spores for oral capsules; and the triple- and quad-therapies specific to H. pylori infections of the stomach that he developed in the 1980s. Dr Borody’s current research builds upon both of these areas, with an emphasis on the application of FMT techniques, donor methodologies and an FMT biobank, as well as understanding the role of infection in neurologic and autoimmune conditions; the development of triple/quad therapy for resistant strains of H. pylori; and the invention and clinical trials of Ziverdox (ivermection / doxycycline / zinc) for the treatment and prevention of COVID-19 infections (currently in clinical trials in Australia and the USA). Earlier in his career, Dr Borody developed bowel preparation products - Glycoprep, Glycoprep-C, Moviprep and Riteprep – all of which are examples of how Australian medical research can translate to global commercialization. Dr Borody is the Director of the Centre for Digestive Diseases in Five Dock, NSW. He serves on GESA’s Clinical Oncology Faculty.